Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farshid Dayyani

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Journal of Gastrointestinal Oncology|May 18, 2023
Medullary carcinoma of the duodenum treated with pembrolizumab: a case reportLouisa Liu, Simmer Kaur, Farshid Dayyani, et al.
Journal of Gastrointestinal Cancer|January 26, 2024
Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal DiseaseAmy Y Li, Shaina Sedighim, Fatemeh Tajik, et al.
Journal of Gastrointestinal Oncology|November 19, 2020
Variability in multimodality treatment influences survival in non-metastatic gastric cancer patientsTuyen Hoang, Farshid Dayyani, Ariceli Alfaro, et al.
Clinical Colorectal Cancer|January 4, 2022
Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment ProtocolMehraneh D Jafari, Joseph C Carmichael, Farshid Dayyani, et al.
Medical Oncology (Northwood, London, England)|May 22, 2022
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimenFarshid Dayyani, Kit Tam, Edward J Kim, et al.
Journal of Thoracic Disease|May 13, 2024
Revealing the oncogenic role of elevated GNL3L expression in esophageal squamous cell carcinoma: insights into the STAT3 pathwayShaobin Yu, Peipei Zhang, Shaojun Xu, et al.
Future Oncology (London, England)|March 13, 2023
A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)Sharmeen Mahmood, Daneng Li, Arielle Lee, et al.
Cancers|May 28, 2022
<i>BRCA</i>-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsNaomie Devico Marciano, Gianna Kroening, Farshid Dayyani, et al.
Clinical Colorectal Cancer|December 16, 2023
A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal AdenocarcinomaFarshid Dayyani, Jasmine Balangue, Jennifer Valerin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNFKai-Uwe Belge, Farshid Dayyani, Alexia Horelt, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Journal of Gastrointestinal Oncology|May 18, 2023
Medullary carcinoma of the duodenum treated with pembrolizumab: a case reportLouisa Liu, Simmer Kaur, Farshid Dayyani, et al.
Journal of Gastrointestinal Cancer|January 26, 2024
Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal DiseaseAmy Y Li, Shaina Sedighim, Fatemeh Tajik, et al.
Journal of Gastrointestinal Oncology|November 19, 2020
Variability in multimodality treatment influences survival in non-metastatic gastric cancer patientsTuyen Hoang, Farshid Dayyani, Ariceli Alfaro, et al.
Clinical Colorectal Cancer|January 4, 2022
Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment ProtocolMehraneh D Jafari, Joseph C Carmichael, Farshid Dayyani, et al.
Medical Oncology (Northwood, London, England)|May 22, 2022
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimenFarshid Dayyani, Kit Tam, Edward J Kim, et al.
Journal of Thoracic Disease|May 13, 2024
Revealing the oncogenic role of elevated GNL3L expression in esophageal squamous cell carcinoma: insights into the STAT3 pathwayShaobin Yu, Peipei Zhang, Shaojun Xu, et al.
Future Oncology (London, England)|March 13, 2023
A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)Sharmeen Mahmood, Daneng Li, Arielle Lee, et al.
Cancers|May 28, 2022
<i>BRCA</i>-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsNaomie Devico Marciano, Gianna Kroening, Farshid Dayyani, et al.
Clinical Colorectal Cancer|December 16, 2023
A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal AdenocarcinomaFarshid Dayyani, Jasmine Balangue, Jennifer Valerin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNFKai-Uwe Belge, Farshid Dayyani, Alexia Horelt, et al.
Pageof 12